$AEMD News
Last published 18h ago
- 18h agoAEMDAETHLON MEDICAL INC - PRESS RELEASEEarnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 18h agoAEMDAethlon Medical Reports Second Quarter Fiscal 2027 Results and Provides Corporate UpdatePR NewswireAethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company, today announced financial results...
- 1mo agoAEMDAethlon Medical, Inc. 2026 Annual Meeting of Stockholders - AETHLON MEDICAL INCEarnings Call TranscriptsThis video tutorial shows how to install Kali Linux 2017.1 LXDE on VMware Workstation or VMware Workspace. Kali LXD is a very simple and easy-to-use software that can be installed on your computer. To install it, click o
- 1mo agoAEMDNTHIBIAFTURBFour High-Impact Small Caps Enter the SpotlightGlobeNewswireDENVER, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The small-cap market is delivering a mix of catalysts, with the following companies in particular putting substantial new developments in front of investors: Aethlon Medical
- 1mo agoAEMDAethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic DermatitisPR NewswireAethlon Medical, Inc. (Nasdaq: AEMD) ("Aethlon" or the "Company") today announced that it has entered into a definitive merger agreement (the...
- 2mo agoMWCSBCNPMMFSKHRF+20Presenting on Emerging Growth Conference 95 Day 2 on August 20; Register to live streamGlobeNewswireMIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 95th Emerging Growth Conference on August 19 & 20, 2026. The Emerging Growth
- 2mo agoMWCSBCNPMMFSKHRF+20Presenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live streamGlobeNewswireMIAMI, Aug. 18, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 95th Emerging Growth Conference on August 19 & 20, 2026. The Emerging
- 3mo agoAEMDAethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® ProgramPR NewswireConference Call Today at 4:30 p.m. ETSAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a clinical-stage medical therapeutic company, today announced financial results
- 3mo agoAEMDAethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026PR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious...
- 3mo agoAEMDEarnings Call - AETHLON MEDICAL INCEarnings Call TranscriptsWelcome back, everyone. Next, we have Athlon Medical, trades on the NASDAQ under the symbol AEMD. It's a medical therapeutic company focused on developing the Hemocurifier, a clinical stage immunotherapeutic device that
- 4mo agoAEMDAethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®PR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company developing products to treat cancer and life-threatening viral infections, today...
- 4mo agoAEMDAethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ RulesPR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious...
- 4mo agoAEMDAethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®PR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious...
- 4mo agoAEMDEarnings Call - AETHLON MEDICAL INCEarnings Call Transcriptsi mentioned this small safety trial that we're doing uh took a while to get it off the ground but i'm pleased to report we've um we're more than two-thirds of the way through it it's small it's a safety trial looking at
- 5mo agoAEMDAethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate UpdatePR NewswireAethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical therapeutic company focused on developing products to treat...
- 5mo agoAEMDAethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026PR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious...
- 5mo agoAEMDAethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic PreparednessPR NewswireAethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious...
- 7mo agoAEMDAethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB ReviewPR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal...
- 8mo agoAEMDAethlon Medical Engages Maxim Group LLC to Evaluate Strategic OpportunitiesPR NewswireAethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and...
- 8mo agoAEMDAethlon Medical to Present at the Life Sciences Investor Forum on March 12thGlobeNewswireSAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious
- 8mo agoAEMDAethlon Medical to Present on the Emerging Growth Conference on February 25th 2026PR NewswireAethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and...
- 9mo agoAEMDContinAethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate UpdatePR NewswireAethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and...
- 9mo agoAEMDAethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026PR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious...
- 11mo agoAEMDAethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 MillionPR NewswireAethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and...
- 11mo agoAEMDAethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAsPR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious...
- 1y agoAEMDCompliAethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate UpdatePR NewswireAethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and...
- 1y agoAEMDAethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025PR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious...
- 1y agoAEMDAethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical TrialPR NewswireAethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD) today provided observations on the preliminary changes in extracellular vesicle...
- 1y agoAEMDAethlon Medical Announces Pricing of $4.5 Million Public OfferingPR NewswireAethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and...
- 1y agoAEMDAethlon Medical, Inc. (AEMD) Q1 2026 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoAEMDAethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2025, and Provides Corporate UpdatePR NewswireAethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and...
- 1y agoAEMDAethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025PR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious...
- 1y agoAEMDAethlon Medical, Inc. Announces Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial CohortPR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal...
- 1y agoAEMDAethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate UpdatePR NewswireAethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and...
- 1y agoAEMDAethlon Medical to Release Fiscal Fourth Quarter Financial Results and Host Conference Call on June 26, 2025PR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious...
- 1y agoAEMDAethlon Medical Treats Second Patient in Australian Hemopurifier® Cancer TrialPR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious...
- 1y agoAEMDAethlon Medical to Present New Pre-Clinical Data at the Keystone Symposium on Long COVID and Other Post-Acute Infection SyndromesPR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious...
- 1y agoAEMDAethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Platelet-Derived Extracellular Vesicles from PlasmaPR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious...
- 1y agoAEMDAethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology JournalPR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious...
- 1y agoAEMDAethlon Medical to Present at the Emerging Growth Conference on February 19, 2025PR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious...
- 1y agoAEMDAethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate UpdatePR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious...
- 1y agoAEMDAethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025PR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious...
- 1y agoAEMDAethlon Medical Treats First Patient in Australian Hemopurifier® Cancer TrialPR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious...
- 1y agoAEMDAethlon Medical Provides Update on the Ability of Its Hemopurifier® to Capture H5N1 Bird FluPR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious...
- 1y agoAEMDAethlon Medical, Inc. (AEMD) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoAEMDAethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate UpdatePR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious...
- 2y agoAEMDAethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier® Cancer Trial in AustraliaPR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious...
- 2y agoAEMDAethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 13, 2024PR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious...
- 2y agoAEMDAethlon Medical to Participate in the 2024 Maxim Healthcare Virtual SummitPR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious...
- 2y agoAEMDAethlon Receives Ethics Committee Approval for Hemopurifier® Cancer Trial in IndiaPR NewswireAethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious...